enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of “Buy” by Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been assigned an average rating of “Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $33.67.

A number of research analysts recently weighed in on ENGN shares. Morgan Stanley reissued an “overweight” rating and set a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and set a $30.00 target price on shares of enGene in a report on Tuesday, September 24th.

Insider Buying and Selling at enGene

In other news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $5.70 per share, with a total value of $57,000.00. Following the acquisition, the chief executive officer now directly owns 10,000 shares in the company, valued at $57,000. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Growth Opportunities F. Forbion acquired 11,844 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was purchased at an average cost of $6.55 per share, for a total transaction of $77,578.20. Following the completion of the acquisition, the insider now owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. This represents a 0.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 420,965 shares of company stock valued at $2,651,103 in the last ninety days. 13.70% of the stock is currently owned by corporate insiders.

Institutional Trading of enGene

A number of institutional investors have recently modified their holdings of ENGN. Janus Henderson Group PLC bought a new stake in shares of enGene during the 1st quarter valued at $17,095,000. Point72 Asset Management L.P. lifted its position in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 619,100 shares during the period. SR One Capital Management LP bought a new stake in shares of enGene during the 2nd quarter valued at $4,715,000. Logos Global Management LP lifted its position in shares of enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after acquiring an additional 400,000 shares during the period. Finally, Altitude Crest Partners Inc. bought a new stake in shares of enGene during the 1st quarter worth $2,039,000. 64.16% of the stock is currently owned by institutional investors.

enGene Trading Down 3.8 %

Shares of ENGN opened at $7.63 on Monday. The firm has a 50-day moving average of $7.66 and a 200-day moving average of $8.71. enGene has a one year low of $4.42 and a one year high of $18.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. Sell-side analysts anticipate that enGene will post -1.54 earnings per share for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.